Lung cancer
Conditions
Interventions
Ametinib mesylate monotherapy group:Administration of ametinib mesylate
Amitinib combined with vincristine group:Co-administration of amitinib and vincristine
Sponsors
Anhui Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients were enrolled only if they met all of the following criteria: 1) Age: =18 years, male or female; 2) Patients with locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations who have not received prior systemic anti-tumour therapy for locally advanced or metastatic non-small cell lung cancer. 3) Patients who, in the opinion of the investigator, would benefit from treatment with alectinib or alectinib in combination with vincristine; 4) Approved by the Ethics Committee, the patient voluntarily participates in this study, signs the informed consent, is compliant, and cooperates with the treatment and follow-up.
Exclusion criteria
Exclusion criteria: Anyone with one of the following conditions will not be selected: 1) Pregnant or lactating women; 2) Patients with contraindications to amitriptyline or EGFR-TKIs (e.g., active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension uncontrollable by medication, class III-IV cardiac insufficiency, within 30 days of major surgery, severe hepatic or renal insufficiency, etc.); 3) Those whom the doctor considers unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival, PFS;Disease Control Rate, DCR;Duration of Overall Response, DOR;Overall Survival, OS;Security Indicators; | — |
Countries
China
Contacts
Public ContactShi Qingming
Anhui Chest Hospital
Outcome results
None listed